ALGS: Aligos Therapeutics, Inc. Company Value to Net Income

Symbol and logo of brand Aligos Therapeutics, Inc. (ALGS)

Aligos Therapeutics (ALGS) focuses on developing therapies for the complete eradication of the hepatitis B virus to eliminate the need for lifelong medication. Potential pricing power is based on the ownership of unique patents. The price indicator on the chart is fixed at -0.20. Currently, the business relies on external research contractors, controlling the quality of each batch through strict audits and long-term contracts.

ALGS - Aligos Therapeutics, Inc. P/E Multiple over the range 07/04/2022 - 11/12/2026

Comprehensive metric breakdowns and analytics for Aligos Therapeutics Inc. (ALGS)

- price and consensus price forecast:
Stock Price Aligos|ALGS - Consensus Target
- market capitalization information:
Market Value Aligos Therapeutics, Inc.|ALGS - Total Company Value
- balance sheet net asset value indicators:
Net Assets per Single Share Aligos Therapeutics|ALGS - Book Capitalization|Market Capitalization to Book Value aligos.com|ALGS - Cumulative Company Assets
- company liabilities and liquidity data:
Debt to Equity Aligos Therapeutics|ALGS - Long-Term Debt to Capital|Current Liabilities to Capital Aligos|ALGS - Company Debts|Debt to Net Assets Ratio Aligos Therapeutics, Inc.|ALGS - Company Long-Term Debts|Company Short-Term Debts Aligos Therapeutics|Quick Liquidity aligos.com
- earnings and market ratios statistics:
ALGS - Net Profit|Company Profit Forecast Aligos Therapeutics|ALGS - P/E Multiple|Forward Price to Earnings Multiple Aligos|ALGS - Price/Earnings to Growth Ratio|Company Value to EBITDA Aligos Therapeutics, Inc.|ALGS - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Aligos Therapeutics|ALGS - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months aligos.com|ALGS - Net earnings per share growth this year|Projected earnings per share increase next year Aligos Therapeutics
Comprehensive company analysis:aligos.com - ALGS
Brand item of Aligos Therapeutics, Inc.

A conservative approach requires evaluating the ratio of an asset's market value to its net income, which determines the extent of the premium paid for future dividends. By analyzing the earnings multiple of Aligos Therapeutics (ALGS), an investor correlates current capitalization with the potential for pricing power expansion within the hepatitis B therapy market, where inelastic demand for unique oligonucleotides could radically alter the fundamental value of the shares.

Key competitors

P/E Multiple arrowheadpharma.com|Price to Earnings Ratio MIRM (Mirum)|DVAX (Dynavax Technologies) - Company Value to Net Income|Price to Earnings Ratio Arbutus ABUS|Inventiva Corp - Price to Earnings Ratio|Gyre Therapeutics, Inc. - P/E Multiple|Business Payback Period assemblybio.com ASMB|GALT (galectintherapeutics.com) - Price to Earnings Ratio|GNFT (GENFIT) - Price to Earnings Ratio|DRRX (DURECT Corp) - P/E Multiple|Market Cap to Earnings BioVie Pharma BIVI|Price to Earnings Ratio Galmed Pharmaceuticals (GLMD)|NDRA (endrainc.com) - Company Value to Net Income|P/E Multiple HEPA (Hepion Pharmaceuticals, Inc.)